Knight TherapeuticsFRA:04K 73 OCF Margin % is 27.41% as of Mar. 2026, which is 109% above its 10-year median of 13.14. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.35. The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Knight Therapeutics ranks better than 78.62% on this metric.
The historical rank and industry rank for Knight Therapeutics's OCF Margin % or its related term are showing as below:
FRA:04K'
s OCF Margin % Range Over the Past 10 Years
Min: -45.91 Med: 13.14 Max: 271.68
Current: 20.8
During the past 13 years, the highest OCF Margin % of Knight Therapeutics was 271.68%. The lowest was -45.91%. And the median was 13.14%.
FRA:04K's OCF Margin % is ranked better than 78.62% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs FRA:04K: 20.80
Knight Therapeutics OCF Margin % Related Terms
Knight Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Knight Therapeutics (FRA:04K) has a OCF Margin % of 27.41% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Knight Therapeutics and its competitors. This is 109% above median its historical median of 13.14. According to the industry distribution chart, Knight Therapeutics ranks #205 out of 959 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Knight Therapeutics' OCF Margin % too high?
Knight Therapeutics' current OCF Margin % of 27.41% is 109% above median its 10-year median of 13.14. The Drug Manufacturers industry median OCF Margin % is 9.95. Knight Therapeutics' value of 27.41% is 175.5% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #205 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #205 out of 959 companies for OCF Margin %. This places Knight Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Knight Therapeutics' value of 27.41% is 175.5% above this benchmark. While the company's 10-year median is 13.14 vs. the industry median of 9.95, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current OCF Margin % of 27.41% is 175.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current OCF Margin % is 27.41%, which is 109% above median its own 10-year median of 13.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current OCF Margin % of 27.41%. The stock's GF Value™ is €5.35, compared to a current price of €5.70 — trading 6.5% above its estimated fair value. The current OCF Margin % is 27.41%, which is 109% above median its 10-year median of 13.14 and 175.5% above the Drug Manufacturers industry median of 9.95. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current OCF Margin % is 27.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €5.70 is trading 6.5% above its estimated GF Value™ of €5.35.
Key valuation signals for FRA:04K:
OCF Margin %: 27.41% (109% above median its 10-year median of 13.14)
GF Value™: €5.35 vs. price of €5.70 (6.5% above fair value)
Industry Position: 175.5% above the Drug Manufacturers median (#205 of 959)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
